日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants

在健康受试者中,替姆沙韦(HIV-1 附着抑制剂前药福司沙韦的活性成分)与考比司他、依曲韦林、达芦那韦/考比司他或达芦那韦/利托那韦(含或不含依曲韦林)联合用药的药代动力学研究

Moore, Katy; Thakkar, Nilay; Magee, Mindy; Sevinsky, Heather; Vakkalagadda, Blisse; Lubin, Susan; Llamoso, Cyril; Ackerman, Peter

Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality

利用以患者为中心的抽样方法进行临床药物开发和分散式临床试验:从承诺到现实

Maass, Katie F; Barfield, Matthew D; Ito, Mototsugu; James, Christopher A; Kavetska, Olga; Kozinn, Marc; Kumar, Parag; Lepak, Maureen; Leuthold, Luc Alexis; Li, Wenkui; Mikhailov, Dmitri; Patel, Shefali; Perez, Nisha L; Jackson Rudd, Deanne; Vakkalagadda, Blisse; Williams, Tracy M; Zha, Jiuhong; Zhang, Xin; Anderson, Melanie D

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

一项针对病毒血症 HIV 患者,采用开放标签、多次递增剂量方案研究抗 CTLA-4 抗体伊匹木单抗的疗效

Colston, Elizabeth; Grasela, Dennis; Gardiner, David; Bucy, R Pat; Vakkalagadda, Blisse; Korman, Alan J; Lowy, Israel

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

一项针对去势抵抗性前列腺癌患者的新型抗雄激素药物BMS-641988的I期剂量递增研究

Rathkopf, Dana; Liu, Glenn; Carducci, Michael A; Eisenberger, Mario A; Anand, Aseem; Morris, Michael J; Slovin, Susan F; Sasaki, Yasutsuna; Takahashi, Shunji; Ozono, Seiichiro; Fung, Nga Kit Eliza; Cheng, Shinta; Gan, Jinping; Gottardis, Marco; Obermeier, Mary T; Reddy, Jyotsna; Zhang, Steven; Vakkalagadda, Blisse J; Alland, Leila; Wilding, George; Scher, Howard I